NCT05441839 UK Heart Failure With Preserved Ejection Fraction
| NCT ID | NCT05441839 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Manchester University NHS Foundation Trust |
| Condition | Heart Failure With Preserved Ejection Fraction (HFpEF) |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2022-10-07 |
| Primary Completion | 2037-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2022-10-07 with a primary completion date of 2037-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Heart failure occurs when the heart is no longer able to pump blood around the body properly. It can cause breathlessness, swollen feet and ankles, and tiredness. In about half of patients with heart failure, one measure of the heart's pumping function, called the 'ejection fraction', is normal. This type of heart failure is called heart failure with preserved ejection fraction, or HFpEF. HFpEF remains poorly understood. It is not clear why some people develop HFpEF, or what determines the severity of the condition. Treatment options may be limited. UK HFpEF is a study that aims to gain a better understanding of why people develop HFpEF, develop better tests to diagnosis it, identify and test new treatments, and follow the health of the people taking part over many years.
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent 2. Diagnosis of HFpEF by a cardiologist with HF expertise, or a primary care physician with HF expertise, or a heart failure nurse 3. Natriuretic peptide levels measured Exclusion Criteria: 1. LV EF \< 40% (at screening or any previous measurement) 2. Known infiltrative cardiomyopathy (e.g., amyloid, sarcoid, lymphoma, endomyocardial fibrosis) 3. Known active myocarditis, constrictive pericarditis, or cardiac tamponade 4. Known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy 5. Known arrhythmogenic right ventricular cardiomyopathy 6. Known severe primary valvular heart disease 7. Known idiopathic, heritable or drug-induced pulmonary arterial hypertension 8. Heart transplantation or ventricular assist device 9. Complex congenital heart disease
Contact & Investigator
Chris Miller, MBChB FRCP
STUDY CHAIR
Manchester University NHS Foundation Trust
Frequently Asked Questions
Who can join the NCT05441839 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure With Preserved Ejection Fraction (HFpEF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05441839 currently recruiting?
Yes, NCT05441839 is actively recruiting participants. Contact the research team at fardad.soltani@mft.nhs.uk for enrollment information.
Where is the NCT05441839 trial being conducted?
This trial is being conducted at Abercynon, United Kingdom, Aylesbury, United Kingdom, Birmingham, United Kingdom, Chelmsford, United Kingdom and 11 additional locations.
Who is sponsoring the NCT05441839 clinical trial?
NCT05441839 is sponsored by Manchester University NHS Foundation Trust. The principal investigator is Chris Miller, MBChB FRCP at Manchester University NHS Foundation Trust. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.